Uncovering the Suboxone Lawsuit Scandal: Negligence, Tooth Decay, and Victims Left in the Dark

Los Angeles, CA – A wave of lawsuits has been filed against Invidior, the maker of the drug Suboxone, alleging that the company failed to adequately warn doctors and patients about the risk of severe tooth decay associated with the medication. The crux of these lawsuits is the claim that Invidior prioritized profit over safety, knowingly withholding information about the drug’s potential dental side effects.

Suboxone is a medication prescribed to treat opioid addiction, and it has been widely used by individuals seeking to overcome their dependency. However, many of these patients were unaware of the potential harm it could cause to their teeth. The lawsuits argue that Invidior should have disclosed the risks associated with the drug, allowing patients to make informed decisions about their treatment options.

One key issue in these lawsuits is the acidity of Suboxone, which has been linked to tooth decay. Despite mounting evidence of this connection, Invidior did not update the drug’s label to include a warning about dental issues until 2022. This failure to inform doctors and patients of the risks has left many individuals grappling with unexpected dental problems as they strive to rebuild their lives after addiction.

The legal landscape surrounding these lawsuits is currently evolving. A Multidistrict Litigation (MDL) is being pursued, which would consolidate the numerous individual cases and streamline the legal process. The defendants have already agreed to this MDL, emphasizing the significance of these claims.

It is important to note that this MDL differs from a class action lawsuit. In an MDL, each individual case remains separate, and plaintiffs may receive their own settlement amount or jury payout. This approach allows for more tailored compensation based on the unique circumstances of each claimant.

The Suboxone MDL is expected to be based in Ohio, where the early stages of the litigation will be coordinated and expedited. However, if a case proceeds to trial, it may be tried in the court where it was initially filed, not necessarily in Ohio.

While a trial is a possibility, historical data suggests that a majority of these lawsuits will ultimately lead to settlements rather than courtroom proceedings. The length of time required for these lawsuits to finalize should be noted, as it may take years before settlement amounts are offered.

Various factors contributed to the slow initial filing of Suboxone tooth decay lawsuits. Questions arose regarding the severity of the injuries and the direct link to Suboxone, as well as concerns about potential contributing factors and the perception of representing former drug addicts. However, recent revelations about Invidior’s alleged profit-driven actions and the undeniable evidence linking Suboxone to tooth decay have motivated some law firms to pursue these cases.

In 2024, our law firm, Miller & Zois, is accepting cases related to tooth decay caused by Suboxone in selected jurisdictions. The statute of limitations is based on when the Suboxone warning was implemented in 2022. Individuals residing in the listed states may contact our team to discuss their situations and determine if legal action is appropriate.

While the exact settlement amounts in these cases are currently unknown and can vary significantly, estimates range from $50,000 to $150,000 for individuals who settle their lawsuits. However, it is vital to recognize that these figures are speculative, and the eventual settlement payouts will depend on the specific circumstances of each case. If the cases proceed to trial, the potential for higher compensation, including punitive damages, exists.

In conclusion, the Suboxone lawsuits represent a legal battle against a pharmaceutical company accused of prioritizing profits over patient safety. The allegations center on Invidior’s alleged failure to adequately warn doctors and patients about the risk of severe tooth decay associated with the drug. As the lawsuits progress through the MDL process, individuals who have experienced dental problems due to Suboxone are pursuing compensation for their damages. The outcome of these cases will significantly impact the future of the pharmaceutical industry’s responsibility in disclosing and addressing potential risks associated with their products.